Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Risk of hepatitis B virus reactivation in patients treated with ibrutinib.

Literature DB >> 29490923

Risk of hepatitis B virus reactivation in patients treated with ibrutinib.

Sarah P Hammond^1,2, Kaiwen Chen^1,2, Alisha Pandit^1,2, Matthew S Davids², Nicolas C Issa^1,2, Francisco M Marty^1,2.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2018 PMID： 29490923 DOI： 10.1182/blood-2018-01-826495

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

Review 1. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.

Authors: Katarzyna Szklener; Adam Michalski; Klaudia Żak; Michał Piwoński; Sławomir Mańdziuk
Journal: Cells Date: 2022-04-14 Impact factor: 7.666

Review 2. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

Authors: Georg Maschmeyer; Julien De Greef; Sibylle C Mellinghoff; Annamaria Nosari; Anne Thiebaut-Bertrand; Anne Bergeron; Tomas Franquet; Nicole M A Blijlevens; Johan A Maertens
Journal: Leukemia Date: 2019-01-30 Impact factor: 11.528

3. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.

Authors: Maria Stefania Infante; Ana Fernández-Cruz; Lucia Núñez; Cecilia Carpio; Ana Jiménez-Ubieto; Javier López-Jiménez; Lourdes Vásquez; Raquel Del Campo; Samuel Romero; Carmen Alonso; Daniel Morillo; Margarita Prat; José Luis Plana; Paola Villafuerte; Gabriela Bastidas; Ana Bocanegra; Ángel Serna; Rodrigo De Nicolás; Juan Marquet; Carmen Mas-Ochoa; Raúl Cordoba; Julio García-Suárez; Alessandra Comai; Xavier Martín; Mariana Bastos-Oreiro; Cristina Seri; Belén Navarro-Matilla; Armando López-Guillermo; Joaquín Martínez-López; José Ángel Hernández-Rivas; Isabel Ruiz-Camps; Carlos Grande
Journal: Cancer Med Date: 2021-09-23 Impact factor: 4.452

4. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Authors: Ying Ni; Lixia Gao; Yan Lu; Shiguang Ye; Lili Zhou; Wenbin Qian; Aibin Liang; Ping Li
Journal: Front Immunol Date: 2022-08-31 Impact factor: 8.786

Risk of hepatitis B virus reactivation in patients treated with ibrutinib.

Review 1. Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.

Review 2. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).

3. Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real-world study.

4. Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

5. Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients.

6. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia

Review 7. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.